基于面板的肿瘤突变负荷测量协调与标准化:QuIP研究的真实世界结果与建议
QuIP研究联合Friends of Cancer Research,用6个panel、15个检测中心分析20例三类肿瘤样本,评估psTMB与wesTMB一致性。wesTMB切点199错义突变对应psTMB 7.8–12.6 mut/Mb,分类一致率74.9%。研究识别固定伪影、DNA投入量、测序深度、基因组覆盖度和VAF切点等混杂因素,建议各panel可用于常规诊断TMB评估并需严格控制参数。
要点
- wesTMB切点199错义突变对应psTMB 7.8–12.6 mut/Mb,分类一致率74.9%
- 固定伪影、DNA投入量、测序深度、覆盖度和VAF切点是psTMB关键混杂因素
核心结论
- 所有评估的panel均可用于常规诊断环境中估计TMB。
- 可靠的组织TMB评估需严格控制固定伪影、DNA投入量、测序深度、基因组覆盖度和VAF切点等参数。
研究设计与样本
- QuIP研究纳入20例样本,来自肺腺癌、头颈鳞癌和结肠腺癌三种肿瘤类型,均有WES数据。
- 使用6个panel在15个检测中心进行psTMB分析,评估实验室间和平台间变异及变异调用与TMB分类一致性。
- 通过经验推导桥接因子将psTMB转换为wesTMB值,并评估胚系过滤的影响。
主要发现
- wesTMB切点199个错义突变投射到psTMB切点为7.8至12.6个突变每兆碱基对,对应psTMB与wesTMB分类一致率为74.9%。
- 以100和300个突变为切点的三级分类中,一致率为76.7%,弱误分类为21.8%,强误分类为1.5%。
- psTMB估计的混杂因素包括固定伪影、DNA投入量、测序深度、基因组覆盖度和变异等位基因频率切点。
关键数值与推荐
- wesTMB切点199个错义突变对应psTMB切点7.8至12.6个突变每兆碱基对。
- 三级分类切点为100和300个突变,一致率76.7%,弱误分类21.8%,强误分类1.5%。
- 87.7%的两两比较Spearman ρ大于0.6。
临床怎么用
- 常规诊断中可使用评估的panel估计组织TMB,但需严格控制固定伪影、DNA投入量、测序深度、基因组覆盖度和VAF切点。
- psTMB与wesTMB分类并非完全一致,临床解读时应关注检测平台和参数设置带来的差异。
局限性
- 研究仅纳入20例样本和三种肿瘤类型,样本量有限。
- psTMB与wesTMB分类一致率未达100%,存在弱误分类和强误分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tumor mutational burden (TMB) is a quantitative assessment of the number of somatic mutations within a tumor genome. Immunotherapy benefit has been associated with TMB assessed by whole-exome sequencing (wesTMB) and gene panel sequencing (psTMB). The initiatives of Quality in Pathology (QuIP) and Friends of Cancer Research have jointly addressed the need for harmonization among TMB testing options in tissues. This QuIP study identifies critical sources of variation in psTMB assessment. METHODS: A total of 20 samples from three tumor types (lung adenocarcinoma, head and neck squamous cell carcinoma, and colon adenocarcinoma) with available WES data were analyzed for psTMB using six panels across 15 testing centers. Interlaboratory and interplatform variation, including agreement on variant calling and TMB classification, were investigated. Bridging factors to transform psTMB to wesTMB values were empirically derived. The impact of germline filtering was evaluated. RESULTS: Sixteen samples had low interlaboratory and interpanel psTMB variation, with 87.7% of pairwise comparisons revealing a Spearman's ρ greater than 0.6. A wesTMB cut point of 199 missense mutations projected to psTMB cut points between 7.8 and 12.6 mutations per megabase pair; the corresponding psTMB and wesTMB classifications agreed in 74.9% of cases. For three-tier classification with cut points of 100 and 300 mutations, agreement was observed in 76.7%, weak misclassification in 21.8%, and strong misclassification in 1.5% of cases. Confounders of psTMB estimation included fixation artifacts, DNA input, sequencing depth, genome coverage, and variant allele frequency cut points. CONCLUSIONS: This study provides real-world evidence that all evaluated panels can be used to estimate TMB in a routine diagnostic setting and identifies important parameters for reliable tissue TMB assessment that require careful control. As complex or composite biomarkers beyond TMB are likely playing an increasing role in therapy prediction, the efforts by QuIP and Friends of Cancer Research also delineate a general framework and blueprint for the evaluation of such assays.
引用
- Stenzinger A, Endris V, Budczies J, et al. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. J Thorac Oncol. 2020. PMID: 32119917. doi:10.1016/j.jtho.2020.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。